Biological effects of myricetin

Ong, K. C. G.; Khoo, Hoon‐Eng

doi:10.1016/s0306-3623(96)00421-1

Cited by 260 publications

(167 citation statements)

References 57 publications

Supporting

Mentioning

158

Contrasting

Unclassified

Order By: Relevance

“…Os sinais em δ 177,57, δ 148,27 e δ 137,21 correspondem, respectivamente, aos carbonos C-4, C-2 e C-3 do esqueleto do fl avonol (Hussein et al, 2003), como sugerido no espectro de RMN 1 H. A análise dos dados espectrais, bem como as comparações com a literatura permitiram identifi car a substância 1 como o 5,7,3',4',5'-penta-hidroxifl avonol, conhecido como miricetina, já descrito na literatura (Hussein et al, 2003), e, ainda, isolado como 3-O-α-L-ramnosídeo das folhas de um espécime de E. malaccensis (Noreen et al, 1998). Essa substância possui reconhecida ação antiinfl amatória, antiosteoporótica, antiarteriosclerótica, antiviral, antioxidante, anticarcinogênica, antidiabética, antitrombose, antimicrobiana e moluscicida (Ong;Khoo, 1997;Carvalho et al, 2000;Kuo, 2005;Barbosa et al, 2006). O espectro de RMN 1 H da substância 2 difere basicamente daquele do fl avonol 1, devido à presença de um sinal adicional, na forma de um simpleto em δ 4,05, integrado para três hidrogênios, atribuível a um grupo metoxila.…”

Section: Resultsunclassified

Estudo fitoquímico e avaliação das atividades moluscicida e larvicida dos extratos da casca do caule e folha de Eugenia malaccensis L. (Myrtaceae)

Oliveira¹,

Humberto²,

Silva³

et al. 2006

Rev. bras. farmacogn.

View full text Add to dashboard Cite

RESUMO:Eugenia malaccensis L. (Syzygium malaccensis Merr.& Perry), denominada comumente de jambo vermelho, é uma espécie arbórea de ocorrência comum no Brasil e faz parte das plantas medicinais do Estado de Alagoas. Estudos químicos anteriores com E. malaccensis foram realizados com plantas coletadas na Ásia, Oceania e na América Central. Este trabalho descreve o estudo químico do extrato etanólico das folhas e cascas de um espécimem coletado no Estado de Alagoas, Brasil. Considerando-se a escassa literatura sobre o potencial moluscicida e larvicida dessa espécie, buscou-se testar estas atividades contra caramujos Biomphalaria glabrata Say, e frente às larvas do mosquito Aedes aegypti L. Os extratos etanólicos da casca do caule e das folhas foram inativos frente às larvas de Aedes aegypti na concentração de 500 μg/mL, porém, ativos contra Biomphalaria glabrata (CL 50 = 42,53 e 41,90 μg/mL, respectivamente). O estudo químico levou ao isolamento e identifi cação de 5,7,3',4',5'-penta-hidroxi-fl avonol (1), 5,7,3',5'-tetra-hidroxi-4'-metoxi-fl avonol (2), ácido 3,4,5-tri-hidroxibenzóico (3) e ácido 3-acetil-urs-12-en-28-óico (4) das folhas e da casca do caule. O composto 4 é isolado pela primeira vez no gênero Eugenia. As estruturas desses compostos foram estabelecidas através de estudos no IV, de RMN 1 H e 13 C e comparação com dados da literatura. Considering that studies on the molluscicidal and larvicidal potential of E. malaccensis were not reported, this work aimed to test its molluscicidal activity against Biomphalaria glabrata snails and larvicidal activity against Aedes aegypti mosquitos. The ethanolic stem bark and leaf extracts were inactive towards Aedes aegypti larvae. The ethanolic stem bark and leaf extract were active against Biomphalaria glabrata with CL 50 = 42.53 and 41.90 μg/mL, respectively. 5,7,3',4',5'-Penta-hydroxy-fl avonol (1), 5,7,3',5'-tetra-hydroxy-4'-methoxyfl avonol (2), 3,4,5-tri-hydroxybenzoic acid (3) and 3-acetyl-urs-12-en-28-oic acid (4) were isolated and identifi ed from the leaves and stem bark. The acid 3β-O-acetyl-urs-12-en-28-oic is for the fi rst time isolated from the genus Eugenia. The structures of the compounds have been established by IR, 1 H and 13 C NMR spectral analysis and by comparison with literature data.

show abstract

Section: Resultsunclassified

Estudo fitoquímico e avaliação das atividades moluscicida e larvicida dos extratos da casca do caule e folha de Eugenia malaccensis L. (Myrtaceae)

Oliveira¹,

Humberto²,

Silva³

et al. 2006

Rev. bras. farmacogn.

View full text Add to dashboard Cite

show abstract

“…66 -68 Many studies indicated that Myr has various biological activities, such as antioxidant, anti-inflammatory, anticarcinogen, and antiviral. 69 Recently, Myr was reported to act as a ␤-secretase inhibitor with reduced production of A␤ in a cell culture study. 70 In this study, the Myr-treated mice showed a decrease in A11-positive oligomers but no change in A␤ plaque burden, as found in Cur, and this agreed with the results of an in vitro study that showed Myr inhibited oligomerization but did not affect fibrillization of A␤.…”

Section: Phenolic Compounds Prevent Ad Pathology 2561mentioning

confidence: 99%

Phenolic Compounds Prevent Alzheimer’s Pathology through Different Effects on the Amyloid-β Aggregation Pathway

Hamaguchi

Ono

Murase

et al. 2009

The American Journal of Pathology

368

256

View full text Add to dashboard Cite

Inhibition of amyloid-␤ (A␤) aggregation is an attractive therapeutic strategy for Alzheimer's disease (AD). Certain phenolic compounds have been reported to have anti-A␤ aggregation effects in vitro.This study systematically investigated the effects of phenolic compounds on AD model transgenic mice (Tg2576). Mice were fed five phenolic compounds (curcumin, ferulic acid, myricetin, nordihydroguaiaretic acid (NDGA), and rosmarinic acid (RA)) for 10 months from the age of 5 months. Immunohistochemically, in both the NDGA-and RA-treated groups, A␤ deposition was significantly decreased in the brain (P < 0.05). In the RA-treated group , the level of Trisbuffered saline (TBS)-soluble A␤ monomers was increased (P < 0.01), whereas that of oligomers, as probed with the A11 antibody (A11-positive oligomers), was decreased (P < 0.001). However, in the NDGA-treated group, the abundance of A11-positive oligomers was increased (P < 0.05) without any change in the levels of TBS-soluble or TBS-insoluble A␤. In the curcumin-and myricetin-treated groups, changes in the A␤ profile were similar to those in the RA-treated group, but A␤ plaque deposition was not significantly decreased. In the ferulic acid-treated group, there was no significant difference in the A␤ profile. These results showed that oral administration of phenolic compounds prevented the development of AD pathology by affecting different A␤ aggregation pathways in vivo. Clinical trials with these compounds are necessary to confirm the anti-AD effects and safety in humans. Alzheimer's disease (AD) is the most common form of dementia, resulting in deterioration of cognitive function and behavioral changes.1 One of the pathological hallmarks of AD is extracellular deposits of aggregated amyloid-␤ protein (A␤) in the brain parenchyma (senile plaques) and cerebral blood vessels (cerebral amyloid angiopathy (CAA)).1 Deposition of high levels of fibrillar A␤ in the AD brain is associated with loss of synapses, impairment of neuronal functions, and loss of neurons. 2-5A␤ was sequenced from meningeal vessels and senile plaques of AD patients and individuals with Down's syndrome.6 -8 The subsequent cloning of the gene encoding the ␤-amyloid precursor protein and its localization to chromosome 21, 9 -12 coupled with the earlier recognition that trisomy 21 (Down's syndrome) invariably leads to the neuropathology of AD, 13 set the stage for the proposal that A␤ accumulation is the primary event in AD pathogenesis. In addition, certain mutations associated with familial AD have been identified within or near the A␤ region of the coding sequence of gene of the amyloid precursor proteins, 14,15 presenilin-1 and presenilin-2, 16 which alter amyloid precursor protein metabolism through a direct effect on ␥-secretase. 17,18 These findings set the stage for the proposal that A␤ aggregation is the primary event in AD pathogenesis and leading to the proposal that anti-A␤ aggregation is a strategy for AD therapy.

show abstract

“…Myricetin (3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4-chromenone), is natural occurring flavanol [28] [29] Table 2. ADMET results of Myricetin and their Analogues.…”

Section: Molecular Docking Resultsmentioning

confidence: 99%

Molecular Docking Studies of Myricetin and Its Analogues against Human PDK-1 Kinase as Candidate Drugs for Cancer

Singh¹,

Srivastava²

2015

CMB

View full text Add to dashboard Cite

Phosphoinositide-dependent protein kinase-1 (PDK1), the class of serine threonine kinase, is a master regulator of the AGC family of kinases. It is a main component of the PI3K pathway. As it is reported that this pathway is most commonly, and this pathway is the most commonly deregulated among many cancers. So designing a selective inhibitor of PDK1 may have the efficacy as an anticancer agent. Herein, we describe our work focused on the structure based on screening of 95% similar analogues of Myricetin deposited in PubChem database as earlier studies have been suggested that myricetin acts as an anti cancer agent. Further molecular docking as well as the in silico ADMET studies are incorporated on these compounds to evaluate the binding and pharmacokinetic properties of these compounds. Due to low oral bioavailability, clinical use of myricetin is limited. Therefore this study is an attempt towards screening of structurally similar better compounds as compare with myricetin which can act as better inhibitor against PDK-1.

show abstract

Biological effects of myricetin

Cited by 260 publications

References 57 publications

Estudo fitoquímico e avaliação das atividades moluscicida e larvicida dos extratos da casca do caule e folha de Eugenia malaccensis L. (Myrtaceae)

Estudo fitoquímico e avaliação das atividades moluscicida e larvicida dos extratos da casca do caule e folha de Eugenia malaccensis L. (Myrtaceae)

Phenolic Compounds Prevent Alzheimer’s Pathology through Different Effects on the Amyloid-β Aggregation Pathway

Molecular Docking Studies of Myricetin and Its Analogues against Human PDK-1 Kinase as Candidate Drugs for Cancer

Contact Info

Product

Resources

About